AbbVie, Harvard Target Emergent Viral Diseases in $30 Million Collaboration
August 25 2020 - 8:47AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Tuesday said it formed a $30 million research
alliance with Harvard University aimed at developing therapies
against emergent viral infections, with a focus on those caused by
coronaviruses and by viruses that lead to hemorrhagic fever.
The North Chicago, Ill., biopharmaceutical company said the
collaboration with Harvard Medical School aims to rapidly integrate
fundamental biology into the preclinical and clinical development
of new therapies for viral diseases that address a variety of
therapeutic modalities.
AbbVie noted that Harvard Medical School has led several
large-scale, coordinated research efforts launched at the outset of
the Covid-19 pandemic.
AbbVie said it will provide $30 million over three years, along
with in-kind support leveraging its scientists, expertise and
facilities to advance collaborative research and early-stage
development efforts across five program areas.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 25, 2020 08:32 ET (12:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2024 to Aug 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2023 to Aug 2024